TBPH Q2 2019 Earnings — Theravance Biopharma, Inc. Revenue & Financial Results | Market Cap Arena

TBPHTheravance Biopharma, Inc.

$697M

Q2 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$26M+11.4% YoY

Gross Profit

-$20M-77.4% margin

Operating Income

-$42M-162.4% margin

Net Income

-$40M-152.3% margin

EPS (Diluted)

$-0.72

QoQ Revenue Growth

+389.9%

Cash Flow

Operating Cash Flow

-$48M

Free Cash Flow

-$49M

Stock-Based Comp.

$11M

Balance Sheet

Total Assets

$492M

Total Liabilities

$630M

Stockholders' Equity

-$137M

Cash & Equivalents

$178M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$26M	$23M	+11.4%
Gross Profit	-$20M	-$24M	+14.6%
Operating Income	-$42M	-$49M	+12.8%
Net Income	-$40M	-$41M	+2.4%

Revenue Segments

License

$19M71%

Collaborative Arrangement Revenue

$8M29%